Improving HIV prevention at bars and other drinking venues in Kenya and Uganda
Innovative strategies to promote biomedical HIV prevention uptake and retention among high-risk adults at drinking venues in Kenya and Uganda
This project works to increase use and continued use of HIV prevention (PrEP and PEP) among adults who drink at bars and similar venues in Kenya and Uganda.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11379203 on NIH RePORTER |
What this research studies
If you visit bars or other drinking venues in Kenya or Uganda, the team will offer combined health screenings, including HIV testing, right where people socialize. They plan to recruit more than 2,000 adults using multi-disease mobilization and have already reached over 75% of adults for HIV testing in pilot work. The project will test different approaches to help people start and stay on PrEP or PEP and link their sexual partners to prevention services. Staff will follow participants over time to see who stays on prevention and whether these efforts lower new HIV infections.
Who could benefit from this research
Good fit: Adults (age 21 and over) who frequently visit alcohol-serving venues in Kenya or Uganda, especially those who drink heavily or have multiple sexual partners, are the ideal candidates.
Not a fit: People under 21, those who do not attend drinking venues, or anyone living outside Kenya or Uganda are unlikely to be directly helped by this project.
Why it matters
Potential benefit: If successful, this work could help more people at high risk start and remain on PrEP/PEP, reducing new HIV infections in these communities.
How similar studies have performed: Programs that added HIV testing to broader health screenings have improved testing uptake, but using venue-based multi-disease mobilization specifically to boost PrEP/PEP at drinking venues is relatively new.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Chamie, Gabriel — University of California, San Francisco
- Study coordinator: Chamie, Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.